Acknowledgements
Melanoma
MELANOMA
The CheckMate 76K trial was funded by Bristol Myers Squibb. We thank the patients and investigators who participated in the CheckMate 76K trial. We acknowledge Ono Pharmaceutical Company for contributions to nivolumab development and Dako, an Agilent Technologies company, for collaborative development of the PD-L1 immunohistochemistry 28-8 pharmDx assay. Findings from CheckMate 76K were reported, in part, at the 20th International Congress of the Society for Melanoma Research. Professional medical writing and editorial assistance were provided by M. Kirk and M. Salernitano of Ashfield MedComms, Inizio Company, and funded by Bristol Myers Squibb; specifically, M. Kirk assisted with the development of the first draft and subsequent revisions, under the direction of the authors, and M. Salernitano provided editorial support for formatting and submission.